206 965-1700
1101 Madison Street, Suite 1500 | Seattle | 98104

Oncology

General and Benign Complex Gynecology

Increase Text Size: A A A

Charles W. Drescher, MD

Research Papers in Referred Journals

2007

  1. Lutz AM, Ray P, Willmann JK, Drescher C, Gambhir SS. 2-Deoxy-2-[F-18]fluoro-D: -glucose Accumulation in Ovarian Carcinoma Cell Lines. Molecular Imaging and Biology. 2007 Sep-Oct;9(5):260-6.
  2. Andersen M, Drescher CW, Zheng Y, Bowen D, Wilson S, Young A, McIntosh M, Mahony B, Lowe K, Urban N. Changes in cancer worry associated with participation in ovarian cancer screening. Psycho-Oncology. 2007 Sept; 16 (9):814-20. doi: 10.1002/pon.1151.
  3. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clinical Cancer Research. 2007 Aug 1;13(15 Pt 1):4422-8.
  4. Goff BA, Mandel LS, Dresher CW, Urban N, Gough S, Schurman KM, Patras J, Mahoney BS, Andersen MR. Development of an ovarian cancer symptom index: Possibilities for earlier detection. Cancer. 2007 Jan 15; 109(2):221-227.

2006

  1. Shah C, Pizer E, Veljovich DS, Drescher CW, Peters WA 3rd, Paley PJ. Clear cell adenocarcinoma of the vagina in a patient with vaginal endometriosis. Gynecologic Oncology. 2006 Dec; 103(3):1130-2.
  2. Urban N, Drescher C. Current and future developments in screening for ovarian cancer. Women's Health. 2006 Sep; 2(5):733-42.
  3. Stewart JJ, White JT, Yan x, Collins S, Drescher CW, Urban ND, Hood L, Lin B. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomics technology and integrated with mRNA expression levels. Molecular and Cellular Proteomics. 2006 Mar;5(3):433-443. Erratum in: Molecular and Cellular Proteomics. 2006 Jun; 5(6):1171.
  4. Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N. Bead-based ELISA for validation of ovarian cancer early detection markers. Clinical Cancer Research. 2006 Apr 1; 12(7 Pt 1):2117-24.
  5. Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen R, McIntosh MW, Disis ML. Antibody immunity to oncogenic proteins is a prognostic indicator in ovarian cancer. Journal of Clinical Oncology. 2006 Feb 10; 24(5):762-8.

2005

  1. Tu SP, Chen H, Chen A, Lim J, May S, Drescher C. Clinical trials: Understanding and perceptions of female Chinese-American cancer patients. Cancer. 2005 Dec 15; 104(12 Suppl):2999-3005.

2004

  1. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecologic Oncology. 2004 Oct;95(1):9-15.
  2. Andersen MR, Nelson J, Peacock S, Giedzinska A, Drescher C, Bowen D, Urban N. Worry about ovarian cancer risk, and use of screening by high-risk women: how you recruit affects what you find. American Journal of Medical Genetics. 2004 Aug 30; 129(2):130-5.
  3. Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening. Cancer Epidemiology, Biomarkers & Prevention. 2004 Apr; 13(4):600-6.

2003 and Earlier

  1. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research. 2003 Jul 1; 63(13):3695-700.
  2. Horowitz NS, Powell MA, Drescher CW, Smith MR, Atwood M, Mate TA, Peters WA. Adequate staging for uterine cancer can be performed through Pfannenstiel incisions. Gynecologic Oncology. 2003 Mar; 88(3):404-10.
  3. Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Graham CL, Smith MR, Drescher CW, Micha JP. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecologic Oncology. 2003 Feb; 88(2):136-40.
  4. Anderson MR, Peacock S, Nelson J, Wilson S, McIntosh M, Drescher C, Urban N. Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer. Gynecologic Oncology. 2002 Apr; 85 (1) 3-8. (Lead article)
  5. Horowitz NS, Peters WA 3rd, Smith MR, Drescher CW, Atwood M, Mate TP. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstetrics and Gynecology. 2002 Feb; 99(2):2335-40.
  6. Peters WA 3rd, Smith MR, Drescher CW. Rectal prolapse in women with other defects of pelvic floor support. American Journal of Obstetrics and Gynecology. 2001 Jun; 184(7):1488-94.
  7. Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube and peritoneum. Gynecologic Oncology. 2001 Dec; 79(3):495-8.
  8. Drescher C, Holt SK, Andersen MR, Anderson G, Urban N. Reported ovarian cancer screening among a population-based sample in Washington State. Obstetrics and Gynecology 2000 Jul 1; 98(1):70-4
  9. Schummer, M, Kiviat N, Bednarski D, Crumb GK, Ben-Dor A, Drescher C, Hood L. Hydribization pf an array of 100,000 cDNAs with 32 tissues finds potential ovarian cancer marker genes. International Journal of Biological Markers, 2000, 15 suppl.1, 35
  10. Cohn DE, Peters WA 3rd, Muntz HG, Wu R, Greer BE, Tamimi HK, Drescher CW, Smith MR, Yon JL, Schmidt R, Goff BA. Adenocarcinoma of the uterine cervix metastatic to lymph nodes. American Journal of Obstetrics and Gynecology, 1998 Jun; 178(6):1131-7
  11. Swisher E, Drescher C. Metastatic placental site throphoblastic tumor: long-term remmission in a patient treated with EMA/CO chemotherapy. Gynecologic Oncology, 1998 Jan; 68(1):62-5.
  12. Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic simulation model to identify an efficient strategy for ovarian cancer screening. Controlled Clinical Trials, 1997; 18:251-270.
  13. Smith MR, Peters WA, Drescher CW. Cisplatin, doxorubicin hydrochloride and cycophosphamide followed by radiotherapy in high-risk endometrial carcinoma. American Journal of Obstetrics and Gynecology, 1994 Jun; 170(6):1677-81.
  14. Drescher CW, Flint A, Hopkins MP, Roberts JA. Prognostic significance of DNA content and nuclear morphology in borderline ovarian tumors. Gynecologic Oncology, 1993 Feb; 48(2):242-6.
  15. Hopkins MP, Drescher CW, McQuillen A, Keyser J, Schmidt R. Malignant placental site trophoblastic tumor associated with placental abruption, fetal distress and elevated CA-125. Gynecologic Oncology, 1992 Nov; 47(2):267-71.
  16. Drescher CW, Reid, GO, Terada K, Roberts JA, Hopkins MP, Perez-Tamayo C, Schoeppel S. Continuous infusion of low dose 5 Fluoruracil and radiation therapy for poor prognostic squamous cell carcinoma of the uterine cervix. Gynecologic Oncology, 1992 Mar; 44(3):227-30.
  17. Van Devanter DB, Yirdew G, Do C, Tyseeling K, Drescher CW, Forseth BJ, Von Hoff DD, McNutt MA, Preparation of uniform, intact DNA samples from resected tumor tissue for pulse-field gel electrophoretic Analysis. BioTechniques, 1992; 41:86.
  18. Drescher CW, Hopkins MP, Roberts JA. A comparison of the pattern of metastatic spread of squamous and adenocarcinoma of uterine cervix. Gynecologic Oncology, 1989 Jun; 33(3):340-3.
  19. Drescher CW, Elkins, TE, Foster RL, Adekeo O. The incidence of urogenital chlamydia trachomatous infections among patients in Kumasi, Ghana. International Journal of Gynecology and Obstetrics, 1988 Dec; 27(30):381-3.
  20. Elkins TE, Drescher CW, Martey JO, Fort D. Vesicovaginal fistula revisited. Obstetrics and Gynecology, 1988 Sep; 72(3Pt1):307-12.
  21. Hopkins MP, Drescher CW, Morley GW. Claudication as a rare symptom of recurrent cervical carcinoma. American Surgeon, 1987 Sep; 53(9):532-3.
  22. Drescher CW, Peters WA, Roberts JA. Contribution of endocervical curettage in evaluating abnormal cervical cytology. Obstetrics and Gynecology, 1983 Sep; 62(3):343-7.

Other Published Scholarly Papers

  1. Urban N, Drescher C. Current and future developments in screening for ovarian cancer. Women's Health 2006, Sep; 2 (5):733-42.
  2. Urban N, Drescher C. Making decisions about screening for ovarian cancer - letter British Medical Journal 2000, April; (320), 940.
  3. Urban N, McIntosh M, Clarke L, Jacobs I, Karlan B, Anderson G, Drescher C, Kiviat N. Socioecominics of ovarian cancer screening. In Sharp F, Blackett A, Berek J, Bast R, eds. Ovarian cancer 6. Oxford: Isis Medical Media 2000.
  4. Urban N, Drescher C, Clarke L, Kiviat N. Cost effectiveness analysis of ovarian cancer screening strategies. In Sharp F, Blackett A, Berek J, Bast R, eds. Ovarian cancer 5. Oxford: Isis Medical Media, 1998.
  5. Drescher CW. Prognostic Significance of DNA ploidy in borderline ovarian tumors. Contemporary OB/ Gyn 49:9 (1995).
  6. Elkins TE, Drescher CW, Martey JO. Cesarean section in developing countries. In: Cesarean Section. J. Phelan, Editor. Willims and Wilkins. 1989.

Invited Talks

  1. Genomics and proteomics - post graduate course -Society of Gynecological Oncologists 34th Annual Meeting, San Diego, California. February 2004
  2. Genomics and proteomics for the Early Detection of Ovarian Cancer- post graduate course- Society of Gynecological Oncologists 33rd Annual Meeting, New Orleans, Louisiana, February, 2003
  3. "Evaluation of pelvic masses" Washington State Obstetrics and Gynecology Annual Meeting Seattle, 1998
  4. "Management of abnormal pap smears" Washington State Obstetrics and Gynecology Annual Meeting Seattle, 1994
  5. "Ovarian cancer-a clinical perspective" Pacific Northwest Diagnostic Ultrasound Symposium, Seattle 1992
  6. "Borderline ovarian tumors" Seattle Gynecological Society, 1990

Presentations and Posters

  1. Brown JV III, Peters WA III, Rettenmaier MA, Drescher CW, Smith MR, Dillman RA, Micha JP. Three consecutive day topotecan is an active regimen for recurrent epithelial ovarian caners, 33rd Annual Meeting SGO, March 17, 2002.
  2. Horowitz NS, Powell MA, Drescher CW, Smith MR, Atwood M, Mate TA, Peters WA III. Adequate staging for uterine cancer can be performed through pfannenstiel incisions. 33rd Annual Meeting SGO, March 17, 2002.
  3. Anderson G, Drescher C, Urban N. Ovarian cancer screening, new perspectives 8th Annual SPORE Workshop, Chantilly Va. July 11, 2000.
  4. Wahl R. Robert, Hopkins M, Drescher CW, Fig L, Mallatia B, Mudgett E, Folsie D, Schroff R, Abrams P, Fer M Wilbur S, PHASE I Evaluation of I-131 Labeled Anti-Ovarian Carcinoma Antibody. Presented at Society of Nuclear Medicine, 87th Annual Meeting, May 19, 1990.
  5. Drescher CW, Hopkins, AM, Roberts JA, Quantitative DNA and Cell Morphometric Evaluation of Ovarian tumors of Low Malignant Potential. Presented at Western Association of Gynecologic Oncologists Annual Meeting. 1990.
  6. Drescher CW, Foster RL, Elkins TE. The Incidence of Urogenital Chlamydia Trachomatous Infection among Patients in Kumasi, Ghana. Presented at The Fourth World Conference of Infectious Diseases and Human Infertility, March 1987.
  7. Ayers JWT, Drescher CW, Randolph JF. Abnormal Gonadotrophin Pulse Frequency Alterations Induced by Clomiphine Citrate in older women. Presented at American Fertility Society 43rd Annual Meeting, 1987.
  8. Drescher CW, Lucchesi BR. An In Vivo Model for development of Intraluminal Coronary Artery Thrombosis in Dogs. Presented at the Midwest Medical Student Research Forum. 1974. Award: Second Place Paper.

Currently Funded Research

National Institutes of Health/National Cancer Institute, P50 CA83636
Pacific Ovarian Cancer Research Consortium: SPORE in Ovarian Cancer
Leadership and Administration Cores
P.I.: Nicole Urban, ScD
Time/Effort: 0.6 calendar months, 5% FTE
Annual Direct Costs: $71,277
Period of Support: 9/30/2004-6/30/2009
Position on Project: Co-Investigator

National Institutes of Health/National Cancer Institute, P50 CA83636
Pacific Ovarian Cancer Research Consortium: SPORE in Ovarian Cancer
Clinical Core- Pacific Ovarian Cancer Research Consortium
P.I.: Charles Drescher, MD
Time/Effort: 1.8 calendar months, 15% FTE
Annual Direct Costs: $128,660
Period of Support: 9/30/2004-6/30/2009

National Institutes of Health/National Cancer Institute, P50 CA83636
Pacific Ovarian Cancer Research Consortium: SPORE in Ovarian Cancer
"Molecular Targets for Prognosis and Therapy" (Project 4)
P.I.: Lee Hood, PhD
Time/Effort: 0.6 calendar months, 5% FTE
Annual Direct Costs: $246,700
Period of Support: 9/30/2004-6/30/2009
Position on Project: Co- PI

National Institutes of Health/National Cancer Institute, P50 CA83636
SPORE Ovarian Cancer Research Program
Inter-SPORE Supplement: "Proteomics Remission Monitoring Trial"
P.I.: Charles Drescher, MD
Time/Effort: 0.6 calendar months, 5% FTE
Annual Direct Costs: $123,198
Period of Support: 9/30/2004-6/30/2007*
*Currently operating under a no cost extension through 6/30/08

National Institutes of Health/National Cancer Institute, P50 CA83636
SPORE Ovarian Cancer Research Program
Inter-SPORE Supplement: "A Phase II Trial of Intraperitoneal Paclitaxel and Carboplatin with IV Bevacizumab Therapy in the Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma of Müllerian Origin"
P.I. Charles Drescher, MD
Time/Effort: Contributed
Annual Direct Costs: $102,073
Period of support: 7/01/2007-6/30/2008

Canary Foundation "Development of a Blood-Based Assay for the Early Detection of Ovarian Cancer"
P.I.: Charles Drescher, MD
Time/Effort: Contributed
Annual Direct Costs: $125,000
Period of Support: 12/1/2005-12/1/2007

Centers for Disease Control, 1R18DP001142-01
"Prevention of Ovarian Cancer in Women Participating in Mammography"
P. I.: Nicole Urban, ScD
Time/Effort: 0.6 calendar months, 5% FTE
Annual Direct Costs: $288,238
Project Period: 9/30/2007 - 09/29/2010

Marsha Rivkin Center for Ovarian Cancer Research
"Rivkin Center Screening Program"
P.I.: Nicole Urban, ScD
Time/Effort: Contributed
Annual Direct Costs: $233,734
Period of Support: 2/01/2006-12/31/2007
Position on Project: Co-PI

Previously Funded Research

National Institutes of Health/National Cancer Institute, RO1 CA96976
"Modeling Ovarian Cancer Screening for CEA"
P.I. Nicole Urban, ScD
Time/Effort: 5%
Annual Direct Costs $166,250
Period of Support: 7/1/02-6/30/06
No-cost extension through 6/30/07
Position on Project: Co-Investigator

Bristol-Myers Squibb
"A Phase II Trial of Single Agent Cetuzimab Dose Escalated to Rash in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma"
P.I.: Charles Drescher, MD
Period of Support: 01/01/05-08/03/06
Position on Project: Principle Investigator

National Institutes of Health/National Cancer Institute, P50 CA83636
SPORE Ovarian Cancer Research Program
Pacific Ovarian Cancer Research Consortium, Developmental Research Project, "Identification of a transcriptional signature of AKT activation in ovarian cancer"
P.I.: Charles Drescher, MD
Time/Effort: 5%
Annual Direct Costs: $28,662
Period of Support: 8/15/2005-8/14/2006

National Institutes of Health/National Cancer Institute, P50 CA83636
"Clinical Core- Pacific Ovarian Cancer Research Consortium", SPORE Ovarian Cancer Research Program
P.I.: Charles Drescher, MD
Time/Effort: 10%
Annual Direct Costs: $196,489
Period of Support: 10/1/99-10/1/04

National Institutes of Health/National Cancer Institute, P50 CA83636
SPORE Ovarian Cancer Research Program
"Genes Associated with Chemoresponsiveness in Ovarian Cancer"
P.I.: Leroy Hood, PhD
Time/Effort: 10%
Annual Direct Costs: $162,280
Period of Support: 10/1/99-10/1/04
Position on Project: Co- Investigator

National Institutes of Health/National Cancer Institute, P50 CA83636
"Collaborative Research on Ovarian Cancer Screening and Chemoprevention", SPORE Ovarian Cancer Research Program/ Inter-SPORE Supplement
P.I.: Nicole Urban, ScD
Time/Effort: 7%
Annual Direct Costs $106,801
Period of Support: 10/1/99-10/1/04
Position on Project: Inter-SPORE Supplement Principal Investigator

National Institutes of Health/National Cancer Institute, P50 CA83636
"Improving Quality of Life for Women with Ovarian Cancer" SPORE Ovarian Cancer Research Program
P.I.: Robyn Andersen, PhD
Time/Effort: 5%
Annual Direct Costs $191,023
Period of Support: 10/1/99-10/1/04
Position on Project: Co- Investigator

National Institutes of Health/National Cancer Institute, U24 CA78164
"CGN Ovarian Cancer Screening Pilot Trial in High Risk Women", Northwest Cancer Genetics Network
P.I.: Deborah Bowen, PhD
Time/Effort: 7%
Annual Direct Costs $104,643
Period of Support: 09/01/01 - 08/31/04
Position on Project: Co-Investigator, Gynecologic Oncologist

National Institutes of Health/National Cancer Institute, P50 CA83636
"Promoting Research Participation Among Chinese American Women", SPORE in Ovarian Cancer
P.I.: Charles W. Drescher, MD
Time/Effort: 5%
Annual Direct Costs: $178,722
Period of Support: 9/01/00-8/31/02

National Institutes of Health/National Cancer Institute, R01 CA75494-01
"Quality of Life Effects of Risk Education and Screening for Ovarian Cancer"
P.I.: Nicole Urban, ScD
Time/Effort: 15%
Annual Direct Cost: $494,297
Period of Support: 9/1/97-8/30/01
No Cost Extension through 8/30/02
Position on Project: Co- Investigator

DOD/US Army Medical Research and Materiel Command, DAMD17-98-1-8649
"Use of Novel Technologies to Identify and Investigate Molecular Markers for Ovarian Cancer Screening and Prevention"
P.I.: Nicole Urban, ScD
Time/Effort: 10%
Annual Direct Cost: $854,545
Period of Support: 10/01/98-09/30/00, No-Cost Extension 10/1/00-0/30/01
Position on Project: Co- Investigator, Gynecologic Oncologist

National Institutes of Health/National Cancer Institute, NO1-CN-65034-29
"A Model for Assessing Cost-Effectiveness of Ovarian Screening"
Supplement to SEER Contract, P.I. David Thomas
Time/Effort: 5%
Annual Direct Cost: $79,965
Period of Support: 9/30/96-9/29/97
Position on Project: Consultant